+

WO2008132167A3 - Diagnostic, prognostic and/or predictive indicators of breast cancer - Google Patents

Diagnostic, prognostic and/or predictive indicators of breast cancer Download PDF

Info

Publication number
WO2008132167A3
WO2008132167A3 PCT/EP2008/055077 EP2008055077W WO2008132167A3 WO 2008132167 A3 WO2008132167 A3 WO 2008132167A3 EP 2008055077 W EP2008055077 W EP 2008055077W WO 2008132167 A3 WO2008132167 A3 WO 2008132167A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognostic
diagnostic
breast cancer
predictive indicators
potential
Prior art date
Application number
PCT/EP2008/055077
Other languages
French (fr)
Other versions
WO2008132167A2 (en
Inventor
Lorraine O'driscoll
Padraig Doolan
Martin Clynes
Original Assignee
Univ Dublin City
Lorraine O'driscoll
Padraig Doolan
Martin Clynes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dublin City, Lorraine O'driscoll, Padraig Doolan, Martin Clynes filed Critical Univ Dublin City
Publication of WO2008132167A2 publication Critical patent/WO2008132167A2/en
Publication of WO2008132167A3 publication Critical patent/WO2008132167A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a novel panel of mRNA markers that have potential as diagnostic, prognostic and/or predictive indicators of breast cancer. Members of this panel also have potential as novel therapeutic targets.
PCT/EP2008/055077 2007-04-26 2008-04-25 Diagnostic, prognostic and/or predictive indicators of breast cancer WO2008132167A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE2007/0308 2007-04-26
IE20070308 2007-04-26

Publications (2)

Publication Number Publication Date
WO2008132167A2 WO2008132167A2 (en) 2008-11-06
WO2008132167A3 true WO2008132167A3 (en) 2009-03-12

Family

ID=39730839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/055077 WO2008132167A2 (en) 2007-04-26 2008-04-25 Diagnostic, prognostic and/or predictive indicators of breast cancer

Country Status (1)

Country Link
WO (1) WO2008132167A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080865A1 (en) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm HEMATOPOIETAL CELLS EXPRESSING SUSD3 PROTEIN AND BINDERS FOR SUSD3 PROTEIN
AU2012296405B2 (en) * 2011-08-16 2016-03-17 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
GB2496150A (en) * 2011-11-02 2013-05-08 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Biomarker and target for responsiveness and resistance to cancer targeting agents
WO2013057323A2 (en) * 2011-10-21 2013-04-25 The Provost, Fellows, Foundation Scholars, And The Other Members Of The Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Marker and target for responsiveness and resistance to cancer agents
US11242565B2 (en) 2015-03-12 2022-02-08 Lucence Life Sciences Pte Ltd. Multigene assay
AT521641B1 (en) * 2018-09-12 2020-07-15 Fianostics Gmbh Procedure for the diagnosis of liver diseases
CN115838802B (en) * 2022-08-29 2025-03-07 山东第一医科大学第一附属医院(山东省千佛山医院) Application of lncRNA PTPRN2-AS1 as a prognostic marker for renal clear cell carcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073207A2 (en) * 2001-03-08 2002-09-19 Cytyc Health Corporation Isolated ductal fluid sample
WO2006022895A2 (en) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
WO2006086638A2 (en) * 2005-02-10 2006-08-17 Board Of Regents, The University Of Texas System Targeting lipocalin-2 for cancer therapeutics
WO2007098102A2 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073207A2 (en) * 2001-03-08 2002-09-19 Cytyc Health Corporation Isolated ductal fluid sample
WO2006022895A2 (en) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
WO2006086638A2 (en) * 2005-02-10 2006-08-17 Board Of Regents, The University Of Texas System Targeting lipocalin-2 for cancer therapeutics
WO2007098102A2 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLEATOR S, ASHWORTH A: "Molecular profiling f breast cancer: clinical implications", BRITISH JOURNAL OF CANCER, vol. 90, 2004, pages 1120 - 1124, XP002496411 *
FERNÁNDEZ CECILIA A ET AL: "The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5390 - 5395, XP002440683, ISSN: 1078-0432 *
STOESZ S P ET AL: "HETEROGENELOUS EXPRESSION OF THE LIPOCALIN NGAL IN PRIMARY BREAST CANCERS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 79, 1 January 1998 (1998-01-01), pages 565 - 572, XP000979576, ISSN: 0020-7136 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2008132167A2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2012068383A3 (en) ncRNA AND USES THEREOF
WO2007123772A3 (en) Genes involved in estrogen metabolism
WO2008132167A3 (en) Diagnostic, prognostic and/or predictive indicators of breast cancer
EP3124624A3 (en) Methylation markers for lung cancer
WO2008046911A3 (en) Novel human micrornas associated with cancer
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2011087845A3 (en) Metabolomic profiling of prostate cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2011034906A3 (en) Recurrent gene fusions in prostate cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2012174256A3 (en) Dna methylation profiles in cancer
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2008089397A3 (en) Adrb2 cancer markers
EP3054299A3 (en) Biomarkers for the early detection of breast cancer
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2008104380A3 (en) Multiplex detection of tumour cells using a panel of agents binding to extracellular markers
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2008046509A8 (en) Ltbp2 as a biomarker, therapeutic and diagnostic target
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08749737

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08749737

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载